The Efficacy and Mechanism of Hydroxychloroquine in Patients with Inflammatory Cardiomyopathy After Myocarditis
Evaluating the long-term therapeutic effects and safety of hydroxychloroquine(compared to glucocorticoid therapy alone) in patients with inflammatory cardiomyopathy--a multicenter randomized controlled study
• Male or female patient aged from 18 to 80 years;
• Left ventricular dysfunction \[left ventricular ejection fraction (LVEF) \<50%\] diagnosed by echocardiography (Simpson's biplane) within 30 days before randomization;
• Chronic heart failure (lasting \>6 months) unresponsive to conventional supportive therapy;
• High-sensitivity cardiac Troponin I (hs-cTnI) \>26.2 pg/mL and N-terminal-pro-B-type natriuretic peptide (NT-proBNP) \>169pg/mL;
• Suffered from confirmed fulminant myocarditis in the past;
• Diagnosed with chronic inflammatory cardiomyopathy confirmed by myocardial biopsy1;
• Absence of cardiotropic viruses at polymerase chain reaction analysis;
• Volunteer for the study and written informed consent;